ABUS vs KIM · P/E 5.4, rev $6.2M vs P/E 27, $16.03B cap
Arbutus Biopharma Corp (ABUS) versus Kimco Realty Corporation (KIM) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Kimco Realty Corporation (KIM) is a reit - retail company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
KIM does not have a complete income-statement cache yet.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. KIM currently screens at market cap $16.03B and trailing P/E 27.3.
Not investment advice. Open the ABUS and KIM stock pages for the full models.
Not investment advice.